Site icon Market Globalist

Why Zosano Pharma Corporation (ZSAN) stock pop up in the after-market on Wednesday?

Zosano Pharma Corporation (ZSAN) shares rallied 26.34% in after-market on Wednesday, May 26, 2021, and close the day at $0.94 per share. Earlier, ZSAN’s stock lost 0.29% in the early trading session. ZSAN shares have fallen 28.46% over the last 12 months, and they have moved up 1.54% in the past week. Over the past three months, the stock has declined 42.77%, while over the past six months, it has surged 25.59%.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Let’s see is there any recent news about the company?

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Publication of Qtrypta™ clinical data

On May 26, 2021, Zosano Pharma Corporation announced the publication of an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” in The Journal of Headache and Pain.

  Read More

The study was designed to assess the safety and efficacy of the repeated use of Qtrypta™ in adults with migraine who suffered at least 2 migraine attacks per month. The results were consistent about the tolerability and efficacy of Qtrypta.

New Board member

On May 25, 2021, Zosano Pharma Corporation appointed Kathy McGee to its board of directors. Ms. McGee has experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development.

Recent financial results

On May 12, 2021, Zosano Pharma Corporation released its financial results for the first quarter ended March 31, 2021.

Q1 2021 financial highlights

Feedback from FDA 

On April 26, 2021, Zosano Pharma Corporation received feedback on the protocol for the pharmacokinetic study required to support the resubmission of the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA)from the U.S. Food and Drug Administration (FDA) Division of Neurology II.

Zosanoestablished an agreement with Worldwide Clinical Trials to conduct the study, which is expected to involve 48 healthy volunteers to generate comparative pharmacokinetic and safety data. The data will be available in the Q3 of 2021 and Zosano expects to resubmit its NDA for Qtrypta™ by the end of 2021, subject to positive results.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 


The ZSAN stock rallied in the after-market on Wednesday after the company announced the publication of improved trial results of Qtrypta. The ZSAN stock can further surge because the positive trial results are always positive news for any pharmaceutical company.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Exit mobile version